New formulation of an old drug in hypertension treatment: the sustained release of captopril from cyclodextrin nanoparticles

Azevedo, Mariangela de Burgos M de; Tasic, Ljubica; Fattori, Juliana; Rodrigues, Fábio H.S.; Cantos, Fabiana C; Ribeiro, Leandro do Prado; Paula, Vanice de; Ianzer, Danielle; Santos, Robson A.S.

doi:10.2147/ijn.s18999

Cited by 13 publications

(1 citation statement)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The inclusion complex between β-cyclodextrin and Ho(acac) 3 , β-CD-Ho(acac) 3 was prepared by dissolving 236.85 mg of β-cyclodextrin in 50.0 mL of water and suspending 52.0 mg of Ho(acac) 3 in it, after stirring for 1 hr 100,101. Then, the suspension was left in the refrigerator for 3 days.…”

Section: Methodsmentioning

confidence: 99%

<p>Poly(3-hydroxi-butyrate-co-3-hydroxy-valerate) (PHB-HV) microparticles loaded with holmium acetylacetonate as potential contrast agents for magnetic resonance images</p>

Azevedo

Melo

Soares

et al. 2019

IJN

View full text Add to dashboard Cite

Introduction Biodegradable polymers that contain radioactive isotopes such as Holmium 166 have potential applications as beta particle emitters in tumor tissues. Also, Ho(III) is paramagnetic, which makes it suitable as a contrast agent for magnetic resonance (MR) images. Methods Holmium acetylacetonate (Ho(acac) 3 ) loaded poly(3-hydroxy-butyrate-co-3-hydroxy-valerate) microspheres, with 5% or 8% of 3-hydroxy-valerate (HV), were prepared by emulsification/evaporation process within 20–53 μm size. Microspheres characterization was done using scanning electron microscopy, energy-dispersive X-ray, and infrared spectroscopies. The release of holmium(III) in sodium phosphate buffer (pH 7.4) was followed for 9 days with inductively coupled plasma. Finally, T 2 and T 2 * magnetic resonance images (MRI) were acquired and compared with the MRI of the inclusion complex of holmium acetylacetonate in some β-cyclodextrins. Results Holmium acetylacetonate loading, evaluated by thermogravimetry, was up to 20 times higher for copolymer with 5% of HV. It was shown that microspheres loaded with Ho(acac) 3 exhibited an accumulation of Ho(III) on their surfaces but were stable over time, as no expressive release of holmium(III) was detected in 9-day exposition to sodium phosphate buffer. Holmium acetylacetonate in both microspheres or inclusion complexes was very efficient in obtaining T 2 and T 2 * weighted images in magnetic resonance, thus, might be used as contrast agents. Conclusion This is the first description of the use of inclusion complexes of holmium acetylacetonate in biodegradable polymers as contrast agents. New investigations are underway to evaluate the resistance of PHB-HV polymer microparticles to nuclear activation to assess their potential for use as radiopharmaceuticals for the treatment of liver cancer.

show abstract

Section: Methodsmentioning

confidence: 99%

<p>Poly(3-hydroxi-butyrate-co-3-hydroxy-valerate) (PHB-HV) microparticles loaded with holmium acetylacetonate as potential contrast agents for magnetic resonance images</p>

Azevedo

Melo

Soares

et al. 2019

IJN

View full text Add to dashboard Cite

show abstract

Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles

Singh

Biswas

Shukla

et al. 2019

Sig Transduct Target Ther

449

223

View full text Add to dashboard Cite

The application of nanomedicines is increasing rapidly with the promise of targeted and efficient drug delivery. Nanomedicines address the shortcomings of conventional therapy, as evidenced by several preclinical and clinical investigations indicating sitespecific drug delivery, reduced side effects, and better treatment outcome. The development of suitable and biocompatible drug delivery vehicles is a prerequisite that has been successfully achieved by using simple and functionalized liposomes, nanoparticles, hydrogels, micelles, dendrimers, and mesoporous particles. A variety of drug delivery vehicles have been established for the targeted and controlled delivery of therapeutic agents in a wide range of chronic diseases, such as diabetes, cancer, atherosclerosis, myocardial ischemia, asthma, pulmonary tuberculosis, Parkinson's disease, and Alzheimer's disease. After successful outcomes in preclinical and clinical trials, many of these drugs have been marketed for human use, such as Abraxane®, Caelyx®, Mepact®, Myocet®, Emend®, and Rapamune®. Apart from drugs/compounds, novel therapeutic agents, such as peptides, nucleic acids (DNA and RNA), and genes have also shown potential to be used as nanomedicines for the treatment of several chronic ailments. However, a large number of extensive clinical trials are still needed to ensure the short-term and long-term effects of nanomedicines in humans. This review discusses the advantages of various drug delivery vehicles for better understanding of their utility in terms of current medical needs. Furthermore, the application of a wide range of nanomedicines is also described in the context of major chronic diseases.

show abstract

Potential Strategies to Reduce Blood Pressure in Treatment-Resistant Hypertension Using Food and Drug Administration–Approved Nanodrug Delivery Platforms

2019

View full text Add to dashboard Cite

Unmet medical need Despite significant progress in pharmacological management of patients with primary hypertension, treatment-resistant hypertension (TRH) is still relatively prevalent among them (1). This condition is defined as blood pressure that remains above goal despite concurrent use of optimal doses of three anti-hypertensive drugs of different classes and exclusion of secondary causes of hypertension (2). Current evidence-based pharmacological approach to TRH targets 3 well-established pathophysiological mechanisms thought to underlie this condition simultaneously: increased sodium and fluid retention, enhanced activation of renin-angiotensin system, and over-reactive sympathetic nervous system (3, 4). Thus, patients with TRH are presently treated with combined daily oral diuretics, angiotensin converting enzyme (ACE) inhibitors/angiotensin receptor blockers and calcium channel blockers (5). If blood pressure remains persistently elevated, daily oral spironolactone, an antagonist of aldosterone receptors, is then added to the 3-drug regimen, which provides significant benefit to patients with hyperaldosteronism (2). However, this poly-pharmacopeia approach is not only insufficient to adequately control blood pressure in a significant population of TRH patients but may also expose patients with TRH to serious adverse events and drug interactions leading eventually to non-adherence and treatment failure. Hence, despite recent advances in hypertension research and therapeutics, TRH still represents a life-threatening medical problem. Consequently, there is an urgent need to develop and test novel, safe and efficacious drugs for TRH to improve long-term clinical management and outcomes of patients. Unfortunately, accomplishing this goal is challenging because current drug development

show abstract

New formulation of an old drug in hypertension treatment: the sustained release of captopril from cyclodextrin nanoparticles

Cited by 13 publications

References 30 publications

<p>Poly(3-hydroxi-butyrate-co-3-hydroxy-valerate) (PHB-HV) microparticles loaded with holmium acetylacetonate as potential contrast agents for magnetic resonance images</p>

<p>Poly(3-hydroxi-butyrate-co-3-hydroxy-valerate) (PHB-HV) microparticles loaded with holmium acetylacetonate as potential contrast agents for magnetic resonance images</p>

Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles

Potential Strategies to Reduce Blood Pressure in Treatment-Resistant Hypertension Using Food and Drug Administration–Approved Nanodrug Delivery Platforms

Contact Info

Product

Resources

About